Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster - 2'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- 3Solar storms have influenced our history – an environmental historian explains how they could also threaten our future
- 46 Well known Ladies' Fragrances On the planet
- 5US FDA investigates Takeda's blood disorder drug after pediatric death
- Moon rush: These private spacecraft will attempt lunar landings in 2026
- 6 US States for Fly Fishing
- 15 Outrageous Cosplay Outfits That Will Blow You Away
- Smooth out Your Funds: Cash The board Simplified
- Moving Pool Highlights for 2024
- The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
- 10 Moves toward Start Your Own Effective Business
- Down to earth Manual for A Modest Hyundai Ioniq Electric for Seniors
- 6 Web-based Lawful Administrations: Extensive Surveys and Elements
